472 related articles for article (PubMed ID: 22463833)
41. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
Hermouet S; Bigot-Corbel E; Harb J
Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
[TBL] [Abstract][Full Text] [Related]
42. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
43. Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis.
Bouvard B; Royer M; Chappard D; Audran M; Hoppé E; Legrand E
Joint Bone Spine; 2010 Mar; 77(2):120-4. PubMed ID: 20097594
[TBL] [Abstract][Full Text] [Related]
44. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
45. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
[TBL] [Abstract][Full Text] [Related]
46. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
[TBL] [Abstract][Full Text] [Related]
47. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
49. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
50. Monoclonal gammopathy of ocular significance (MGOS) - a short survey of corneal manifestations and treatment outcomes.
Garderet L; Al Hariri M; Wasielica-Poslednik J; Munder M; Kormányos K; Pena C; Gozzetti A; Zhou X; Waszczuk-Gajda A; Rosinol L; Mikala G; Krzystanski M; Lisch W; Vesole D; Szentmáry N; Jurczyszyn A
Leuk Lymphoma; 2022 Apr; 63(4):984-990. PubMed ID: 34823428
[TBL] [Abstract][Full Text] [Related]
51. Epidemiology of monoclonal gammopathy in Morocco - A hospital-based study.
Ouzzif Z; Doghmi K; Messaoudi N; Bouhsain S; El Machtani S; Biaz A; Rachid A; Dami A; Bezza A; El Maataoui A
Cancer Rep (Hoboken); 2023 May; 6(5):e1814. PubMed ID: 36999311
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
53. [Monoclonal gammopathies].
Abildgaard N
Ugeskr Laeger; 2021 Oct; 183(42):. PubMed ID: 34709161
[TBL] [Abstract][Full Text] [Related]
54. Clinical characteristics and outcomes in biclonal gammopathies.
Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
[TBL] [Abstract][Full Text] [Related]
55. Single monoclonal spike characterized as double monoclonal gammopathy in a patient with multiple myeloma: A rare finding.
Saijpaul R; Khurana V; Verma R; Kaushik S
Indian J Pathol Microbiol; 2024; 67(1):192-194. PubMed ID: 38358220
[TBL] [Abstract][Full Text] [Related]
56. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
57. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
Landgren O; Rajkumar SV
Semin Hematol; 2011 Jan; 48(1):66-72. PubMed ID: 21232660
[TBL] [Abstract][Full Text] [Related]
58. [Conduct in case of monoclonal gammapathy ?].
Decaux O
Rev Prat; 2018 Sep; 68(7):777-784. PubMed ID: 30869332
[TBL] [Abstract][Full Text] [Related]
59. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
[TBL] [Abstract][Full Text] [Related]
60. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]